59
Participants
Start Date
December 31, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
beclomethasone+formoterol 50/6 (1 inhalation)
CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
CHF 1535 50/6 (2 inhalations)
CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
CHF 1535 50/6 (4 inhalations)
CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
Formoterol + Beclomethasone dipropionate
"* Formoterol HFA pMDI 6 µg / actuation~* Extrafine BDP HFA pMDI 50 µg/actuation"
Placebo (6 inhalations)
Matched placebo via pMDI
Zaporizhzhia State Medical University, Zaporizhzhia
Poradnia Alergologiczna, Dębica
Chiesi Farmaceutici S.p.A.
INDUSTRY